NOVOB80.BK Novo Nordisk A/S

- THB
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
2.87%
Fundamental score
-

Is NOVOB80.BK undervalued?

Graham number

The Graham number of Novo Nordisk A/S cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Novo Nordisk A/S fundamental analysis

No fundamental analysis for Novo Nordisk A/S yet.

Novo Nordisk A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone repla…

Full company profile